0000899243-21-007386.txt : 20210219 0000899243-21-007386.hdr.sgml : 20210219 20210219162618 ACCESSION NUMBER: 0000899243-21-007386 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201203 FILED AS OF DATE: 20210219 DATE AS OF CHANGE: 20210219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harding Thomas C. CENTRAL INDEX KEY: 0001834833 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 21656302 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY, SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2020-12-03 2020-12-07 0 0001466301 Clovis Oncology, Inc. CLVS 0001834833 Harding Thomas C. C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 1976 I By wife Stock Option (right to buy) 76.65 2027-09-01 Common Stock 6000 I By wife Stock Option (right to buy) 8.29 2030-01-31 Common Stock 500 I By wife Restricted Stock Units 2028-03-01 Common Stock 93 I By wife Restricted Stock Units 2029-02-01 Common Stock 1250 I By wife Restricted Stock Units 2030-01-31 Common Stock 2900 I By wife These shares were omitted from the reporting person's original Form 3, and also were omitted from two Forms 4 filed by the reporting person after his original Form 3 was filed. On September 5, 2017, the reporting person was granted 6,000 options. The option vested as to 25% of the shares on September 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3. On January 31, 2020, the reporting person was granted 500 options. The option vested as to 25% of the shares on January 31, 2021, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3. On March 1, 2018, the reporting person was granted 297 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3. On February 1, 2019, the reporting person was granted 2,500 Restricted Stock Units. 50% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests on February 1, 2021. These shares were omitted from the reporting person's original Form 3. On January 31, 2020, the reporting person was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vests on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3. Each Restricted Stock Unit represents the right to receive one share of Common Stock. Senior Vice President and Chief Scientific Officer /s/ Thomas C. Harding 2021-02-19